In April 2004, Valeant Pharmaceutical International administered through PharmaNet, LLC contacted the Clinical Trials and Research Unit to participate in a Randomized, Double-Blinded Multi-Centered Study to compare the safety and efficacy of Viraminde to Ribavirin in Threatment-Naïve Patients with Chronic Hepatitis C. On April 22, 2004, PharmaNet, LLC notified the County that our site was selected to participate in the clinical trial. The County will receive $92,800 for fiscal year 2004-2006, if 20 patients are enrolled successfully into the study.
The primary purpose of this study is to assess the safety and effectiveness of 24 months treatment comparing the safety and efficacy of Viraminde to Ribavirin in Threatment-Naïve Patients with Chronic Hepatitis C.
Outcome Objectives
The following outcome objectives related to this project will be measured in 2004-2006 using an Evaluation Work Plan included in the grant proposal:
Outcome Measures
(at end of first year)
2004-2006
Objectives
Percentage of project client goal (20 persons) recruited and assessed for this study.
75%
Percentage of project client’s dosage comparisons completed for this study.
100%
Percentage of project clients with positive response to trial medications
25%
|